Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Mechanical Thrombectomy in Tandem Lesion: Effects of Extracranial Carotid Dissection Versus Atherosclerosis

Author:Quispe-Orozco, Darko   Galecio-Castillo, Milagros   Jumaa, Mouhammad   Divani, Afshin   Ribo, Marc   Abraham, Michael   Petersen, Nils   Fifi, Johanna   Guerrero, Waldo   Malik, Amer   Siegler, James   Nguyen, Thanh   Sheth, Sunil   Yoo, Albert   Linares, Guillermo   Janjua, Nazli   Tekle, Wondwossen   Abdalkader, Mohamad   Soomro, Jazba   Vivanco-Suarez, Juan   Rodriguez-Calienes, Aaron   Mokin, Maxim   Yavagal, Dileep   Hassan, Ameer   Ortega Gutierrez, Santiago   

Session Name:S6: Stroke Pathophysiology and Prediction  

Topic:Cerebrovascular Disease and Interventional Neurology  

Program Number:S6.006  

Author Institution:University of Iowa Hospitals and Clinics, Iowa City, IA  ProMedica Stroke Network, Toledo, OH  University of New Mexico, Albuquerque, NM  Hospital vall d'Hebron, Barcelona, Spain  The University of Kansas Health System, Kansas City, KS  Yale University, New Haven, CT  Mount Sinai Hospital, New York, NY  University of South Florida College of Medicine , Tampa, FL  University of Miami Miller School of Medicine, Miami, FL  University of Chicago, Chicago, IL  Boston Medical Center, Boston, MA  University of Texas At Houston, Houston, TX  Texas Stroke Institute, Dallas, TX  Saint Louis University, Philadelphia, PA  Pomona Valley Hospital Medical Center, Montclair, CA  Valley Baptist Medical Center, Harlingen, TX  Boston Medical Center Deptartment Of Radiology, Boston, MA  Texas Stroke Institute, Plano, TX  University of South Florida, Tampa, FL  

Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Hauser, Stephen   Bar-Or, Amit   Gold, Ralf   Montalban, Xavier   Cohen, Jeffrey   Robertson, Derrick   Hersh, Carrie   Naismith, Robert   Deiva, Kumaran   Bhatt, Alit   Fu, Haoyi   Boer, Ibolya   Meuth, Sven   Cross, Anne   Gärtner, Jutta   Kappos, Ludwig   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.003  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma, USA, Oklahoma City, OK  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA, San Francisco, CA  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Department of Neurology, Katholisches Klinikum Bochum, Ruhr-Universität Bochum, Bochum, Germany, Bochum, Germany  Department of Neurology Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, Florida, USA, Tampa, FL  Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States, Las Vegas, NV  Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA, Saint Louis, MO  Department of Pediatric Neurology, University Hospitals Paris Saclay, Hôpital Bicêtre, National Reference Center for Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology, Section of Neuroimmunology, Washington University School of Medicine, Saint Louis, Missouri, USA, Clayton, MO  Department of Paediatrics and Adolescent Medicine, Division of Paediatric Neurology, University Medical Centre Göttingen, Georg August University Göttingen, Göttingen, Germany, Göttingen, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Organs, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Author:Leist, Thomas   Hauser, Stephen   Derfuss, Tobias   Wiendl, Heinz   Arnold, Douglas   Montalban, Xavier   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Ziemssen, Tjalf   

Session Name:S42: Multiple Sclerosis: Biomarkers/Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:S42.003  

Author Institution:Thomas Jefferson University, Philadelphia, PA, USA, Philadelphia, PA  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, Montreal, QC, Canada  Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland , Basel, Switzerland  Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany  

Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study

Author:Boer, Ibolya   Cree, Bruce   Wiendl, Heinz   Cross, Anne   Delgado, Sylvia   Habek, Mario   Khachanova, Natalia   Ward, Brian   Totolyan, Natalia   Mancione, Linda   Sullivan, Roseanne   Zielman, Ronald   Hu, Xixi   Das Gupta, Ayan   Montalban, Xavier   Winthrop, Kevin   

Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1  

Topic:Multiple Sclerosis  

Program Number:P1.010  

Author Institution:Novartis Pharma AG, Basel, Switzerland  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Washington University School of Medicine, Saint Louis, MO  University of Miami Miller School of Medicine, Miami, FL  University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia  Pirogov Russian National Research Medical University, Moscow, Russian Federation  Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada  First Saint Petersburg State Medical University, St Petersburg , Russian Federation  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V, Amsterdam, Netherlands  Novartis Healthcare Private Limited, Hyderabad, India  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  School of Public Health at Oregon Health & Science University, Portland, OR